Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
590M
-
Number of holders
-
1243
-
Total 13F shares, excl. options
-
501M
-
Shares change
-
+4.21M
-
Total reported value, excl. options
-
$39.2B
-
Value change
-
+$340M
-
Put/Call ratio
-
0.52
-
Number of buys
-
561
-
Number of sells
-
-549
-
Price
-
$78.21
Significant Holders of Edwards Lifesciences Corp - Common Stock (EW) as of Q2 2025
1,397 filings reported holding EW - Edwards Lifesciences Corp - Common Stock as of Q2 2025.
Edwards Lifesciences Corp - Common Stock (EW) has 1,243 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 501M shares
of 590M outstanding shares and own 84.94% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (70M shares), BlackRock, Inc. (55.6M shares), JPMORGAN CHASE & CO (26.8M shares), STATE STREET CORP (25.6M shares), WELLINGTON MANAGEMENT GROUP LLP (19.8M shares), Bank of New York Mellon Corp (17.6M shares), CITADEL ADVISORS LLC (12.7M shares), GEODE CAPITAL MANAGEMENT, LLC (12.7M shares), JENNISON ASSOCIATES LLC (11.7M shares), and DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main (9.13M shares).
This table shows the top 1243 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.